This article is more than 5 years old. Information may no longer be current.
Baseline subfoveal choroidal thickness portends amount of decrease in fovea, central macula after anti-VEGF treatment
Click Here to Manage Email Alerts
ORLANDO, Fla. — Eyes with thinner baseline subfoveal choroidal thickness decreased more rapidly in foveal thickness and central macular thickness after intravitreal anti-VEGF injections, according to a poster presentation here.
“We demonstrate eyes with thicker baseline subfoveal choroidal thickness (SFCT) had greater anatomic and visual gains after three serial intravitreal anti-VEGF injections,” Nika Bagheri, MD, and colleagues said in the poster at the Association for Research in Vision and Ophthalmology meeting.
The retrospective consecutive case series included 57 eyes of 45 patients with diabetic macular edema who had not received previous injections or laser treatments. Twenty-four eyes were treated with intravitreal Avastin (bevacizumab, Genentech) injections, 18 eyes were treated with intravitreal Lucentis (ranibizumab, Genentech) injections and 15 patients were treated with both types of anti-VEGF.
Mean baseline central macular thickness was 462 µm and mean baseline SFCT was 219 µm, the study said.
“Baseline SFCT may help predict which eyes with DME will respond more favorably in the short term to intravitreal anti-VEGF pharmacotherapy,” the poster said.
Disclosure: Bagheri has no relevant financial disclosures.